For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called "antigens"). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Köhler - scientists at the Roche-funded Basel Institute for Immunology - who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological research and built the basis for the use of therapeutic antibodies in medicine and for the entire biotechnology industry.
Scope of the Report:
This report studies the Monoclonal Mouse Antibody market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Monoclonal Mouse Antibody market by product type and applications/end industries.
For antibody discovery, mice are one of the most important sources. They produce similar antibody isotypes with human, including IgA, IgD, IgE, IgG and IgM. Compared with the subclasses of human antibody isotypes, mice contain only one IgA class and the IgG subclasses are known as IgG1, IgG2a, IgG2b and IgG3. In addition, laboratory mice can induce a good immune response to a great range of antigens, even those highly homological human proteins. Moreover, some treatments that unacceptable for humans can also be aboveboard applied for mice with results which are analogous to that from humans. Therefore, the development of mouse monoclonal antibodies is a common choice for a variety of therapeutics and pathology researches. Up to now, the rapid development of therapeutic antibody in the pharmaceutical industry has enabled the mice to play an important role in both monoclonal antibodies discovery and the pre-clinical assessment.
The key players are Roche, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Pfizer, Bayer, Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Biogen, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Seattle Genetics and so on.
The leading companies own the advantages on better performance, more abundant product's types, better technical and impeccable after-sales service. Consequently, they take the majority of the market share of high-end market. Looking to the future years, the slow downward price trend in recent years will maintain. As competition intensifies, prices gap between different brands will go narrowing. Similarly, there will be fluctuation in gross margin.
The global Monoclonal Mouse Antibody market is valued at 7330 million USD in 2017 and is expected to reach 9990 million USD by the end of 2023, growing at a CAGR of 5.3% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Monoclonal Mouse Antibody.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Johnson & Johnson
- Bristol-Myers Squibb
- Alexion Pharmaceuticals
- Seattle Genetics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into